abstract: @entity26 sensor prolyl hydroxylases (PHDs) play important roles in the regulation of HIF-a and cell metabolisms. This study was designed to investigate the direct role of @entity34925 in high fat-diet (HFD)-induced @entity299 . In HFD fed @entity19 , @entity34925 expression was increased without significant changes in @entity71957 and @entity61361 levels in the heart. This was accompanied by a significant upregulation of @entity5001 ( @entity5001 ) and NF-kB. To explore the role of @entity34925 in HFD-induced @entity299 , @entity34925 conditional knockout @entity19 were fed a HFD for 16 weeks. Intriguingly, knockout of @entity34925 significantly reduced @entity5001 and NF-kb expression in HFD @entity19 hearts. Moreover, knockout of @entity34925 inhibited @entity637 and @entity8024 expression, and reduced cell apoptosis and macrophage infiltration in HFD @entity19 . This was accompanied by a significant improvement of cardiac function. Most importantly, conditional knockout of @entity34925 at late stage in HFD @entity19 significantly improved @entity413 tolerance and reversed @entity299 . Our studies demonstrate that @entity34925 activity is a critical contributor to the HFD-induced @entity299 . Inhibition of @entity34925 attenuates HFD-induced @entity299 by a mechanism involving suppression of @entity5001 /NF-kb pathway and @entity32 .

title: Conditional knockout of prolyl hydroxylase domain protein 2 attenuates high fat-diet-induced XXXX in @entity19 .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['Oxygen']

entities_list: @entity5001 :: ('17874(Tax:10090)', 'Gene') :: ['myeloid differentiation factor 88', 'MYD88']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac dysfunction']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity299 :: (MESH:D006331,Disease) :: ['cardiac dysfunction']


abstract: @entity26 sensor prolyl hydroxylases (PHDs) play important roles in the regulation of HIF-a and cell metabolisms. This study was designed to investigate the direct role of @entity34925 in high fat-diet (HFD)-induced @entity299 . In HFD fed @entity19 , @entity34925 expression was increased without significant changes in @entity71957 and @entity61361 levels in the heart. This was accompanied by a significant upregulation of @entity5001 ( @entity5001 ) and NF-kB. To explore the role of @entity34925 in HFD-induced @entity299 , @entity34925 conditional knockout @entity19 were fed a HFD for 16 weeks. Intriguingly, knockout of @entity34925 significantly reduced @entity5001 and NF-kb expression in HFD @entity19 hearts. Moreover, knockout of @entity34925 inhibited @entity637 and @entity8024 expression, and reduced cell apoptosis and macrophage infiltration in HFD @entity19 . This was accompanied by a significant improvement of cardiac function. Most importantly, conditional knockout of @entity34925 at late stage in HFD @entity19 significantly improved @entity413 tolerance and reversed @entity299 . Our studies demonstrate that @entity34925 activity is a critical contributor to the HFD-induced @entity299 . Inhibition of @entity34925 attenuates HFD-induced @entity299 by a mechanism involving suppression of @entity5001 /NF-kb pathway and @entity32 .

title: Conditional knockout of prolyl hydroxylase domain protein 2 attenuates high fat-diet-induced @entity299 in XXXX .

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: BACKGROUND: To investigate lifetime history of interpersonal abuse and risk of @entity308 in socio-economically distinct populations in the same city. METHODS: We examined associations of physical and @entity458 with the risk of @entity308 in two cohorts in the Boston area, including 2128 @entity1 recruited from a large urban- and suburban-managed care organization (Project Viva) and 1509 @entity1 recruited primarily from urban community health centres (Project ACCESS). Protocols for the studies were designed in parallel to allow us to merge data to enhance ethnic and socio-economic diversity in the combined sample. In mid-pregnancy, the Personal Safety Questionnaire and Edinburgh Postnatal Depression Scale (EPDS) were administered in both cohorts. An EPDS score >=  13 indicated probable @entity308 . Logistic regression was used to estimate the odds ratio (OR) of @entity308 associated with lifetime abuse history. RESULTS: Project ACCESS @entity1 were twice as likely as Project Viva @entity1 to report symptoms consistent with @entity308 : 22% of Project ACCESS @entity1 had EPDS scores >=  13, compared with 11% of Project Viva @entity1 . Fifty-seven percent of @entity1 in ACCESS and 46% in Viva reported lifetime physical and/or @entity458 . In merged analysis, @entity1 reporting lifetime physical or @entity458 had an OR for mid-pregnancy @entity308 of 1.63 [95% confidence interval (95% CI): 1.29-2.07], adjusted for age and race/ethnicity. Lifetime histories of physical abuse [OR 1.48 (95% CI 1.15-1.90)] and @entity458 [OR 1.68 (95% CI 1.24-2.28)] were independently associated with @entity308 . When @entity1 /teen, pre-pregnancy adult and pregnancy life periods were considered simultaneously, abuse in childhood was independently associated with an OR of 1.23 (95% CI 1.00-1.59), pre-pregnancy adult abuse with an OR of 1.70 (95% CI 1.31-2.21) and abuse during pregnancy with an OR of 1.77 (95% CI 1.14-2.74). Further adjustment for childhood socio-economic position made no material difference, and there were no clear interactions between abuse and adult socio-economic position. CONCLUSIONS: Physical and @entity458 histories were positively associated with @entity308 in two economically and ethnically distinct populations. Stronger associations with recent abuse may indicate that the association of abuse with @entity308 wanes with time or may result from less accurate recall of remote events.

title: Lifetime maternal experiences of abuse and risk of XXXX in two demographically distinct populations in Boston.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'child']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['pre-natal depression', 'depression']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['sexual abuse']

answer: @entity308 :: (MESH:D003866,Disease) :: ['pre-natal depression']


abstract: Chemical investigation of Guarea kunthiana fruits, guided by their effect on the reproductive cycle of engorged females of the @entity291 tick Rhipicephalus (Boophilus) microplus-a major economic problem to the livestock industry worldwide-led to isolation of 3b-O-tigloylmelianol, a new protolimonoid, from the bioactive @entity4315 phase obtained by partitioning the crude @entity1068 extract. An adult immersion test was performed. The compound strongly inhibited egg-laying and hatchability (99.2% effectiveness at a 0.01% concentration). @entity71958 , isolated from the same phase, yielded unremarkable results in the adult immersion test. From the @entity1044 phase, melianol, @entity71959 , meliantriol, and a new protolimonoid, 3b-O-tigloylmeliantriol, were isolated, all of which, in the same manner as @entity71958 , exhibited unremarkable results in the test. The structures of new and known compounds were mostly established by 1D- and 2D-NMR analyses and mass spectrometry data. This is the first report on the bioactivity of protolimonoids on the reproductive cycle of engorged females of R. (B.) microplus. 3b-O-Tigloylmelianol proved a promising candidate for the development of a biocontrol agent against the @entity291 tick investigated, as an alternative to environmentally hazardous synthetic acaricides.

title: 3b-O-Tigloylmelianol from Guarea kunthiana: A New Potential Agent to Control Rhipicephalus (Boophilus) microplus, a XXXX Tick of Veterinary Significance.

entities_list: @entity71959 :: ('MESH:C434111', 'Chemical') :: ['melianodiol']

entities_list: @entity1044 :: ('MESH:D008752', 'Chemical') :: ['dichloromethane']

entities_list: @entity71958 :: ('MESH:C434112', 'Chemical') :: ['Melianone', 'melianone']

answer: @entity291 :: (9913,Species) :: ['Cattle']


abstract: Diverse microarray and sequencing technologies have been widely used to characterize molecular changes in malignant epithelial cells in salivary neoplasms. Such gene expression studies to identify markers and targets in @entity5 cells are, however, compromised by the cellular heterogeneity of these @entity5 and by the difficulties to accrue matching controls representing normal salivary glands. Seventeen samples of primary @entity189 along with tissue from six normal major salivary glands were microdissected from @entity982 -embedded tissue. Pools of RNA from highly enriched preparations of these cell types were subjected to expression profiling using a whole-transcriptome shotgun sequencing experiment. In parallel, extracted genomic DNA was used for the 50 gene hotspot panel sequenome. @entity984 mutations in three @entity1 (18%), @entity8497 mutations in one @entity1 (6%), but no @entity8498 , MET, @entity10160 , or @entity817 mutations. Using strict and conservative criteria, 220 differentially expressed transcripts were found, with 36% up- and 64% downregulated. The transcripts were annotated using NCBI Entrez Gene, and computationally analyzed with the Ingenuity Pathway Analysis program. From these significantly changed expressions, the analysis identified 26 @entity5 -related transcripts and 16 transcripts related to @entity2383 overlapping with three @entity5 -related genes. These 220 differentially expressed genes including microRNAs provide here a sufficiently large set to specifically @entity189 and to identify novel and potentially important targets for diagnosis, prognosis, and therapy of this @entity5 .

title: Global transcriptome and sequenome analysis of formalin-fixed XXXX specimens.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['salivary epithelial-myoepithelial carcinoma', 'define epithelial-myoepithelial carcinoma']

entities_list: @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin']

entities_list: @entity2383 :: ('MESH:D028361', 'Disease') :: ['mitochondrial dysfunction']

answer: @entity189 :: (MESH:D002277,Disease) :: ['salivary epithelial-myoepithelial carcinoma']


abstract: The present paper describes a case of shoe @entity5526 from DMF identified by the Poison Control Centre of Milan (PCCM), Italy, in 2009. A 35 year old @entity1 was affected by irritant reactions while wearing shoes contaminated with @entity9104 . Exposure to these shoes was limited to a 8 hour period and was not repeated. In the following days the @entity1 suffered feet blistering and swelling limited to the area in contact with shoe vamp. Topical application of @entity821 did not prevent development of @entity484 . After 20 days from exposure, the lesions were healed but the skin remained red, dry and very sensitive. Chemical analyses of shoes quantified an average concentration of DMF of 383 mg/kg. The @entity1 refused to be patch tested. The observation here reported confirm that DMF should be considered a possible causal agent in shoe @entity5526 . Documentation of cases exposed to this chemical provide a relevant support to characterize clinical manifestations and to identifying contaminated articles.

title: A case of XXXX to dimethylfumarate in shoes identified in Italy.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity821 :: ('MESH:D003348', 'Chemical') :: ['cortisone']

entities_list: @entity5526 :: ('MESH:D003877', 'Disease') :: ['contact dermatitis']

entities_list: @entity484 :: ('MESH:D004485', 'Disease') :: ['bullous eczema']

answer: @entity5526 :: (MESH:D003877,Disease) :: ['contact dermatitis']


abstract: The relationship within @entity7533 ( @entity7533 ) pairs is based on pair-bond formation. This pair-bond is important for the successful rearing of the young and for the enhancement of reproductive success. Female marmosets bear twins which are carried mainly by males starting on the first day after the birth of the @entity1 . Little is known, however, about the patterns of sociosexual interaction between callitrichid pairs and how these interactions change after the arrival of offspring. To evaluate the effect of parturition on these interactions, three @entity13635 of @entity7533 were observed for four weeks before and four weeks after the birth of @entity1 . The animals were kept in individual outdoor cages of the Nucleo de Primatologia, under environmental conditions. The time spent in proximity was mainly attributable to the initiative of females before parturition and the initiative of males after the offspring arrived. Males were groomed more before than after the birth of @entity1 . In contrast, the amount of grooming received by females was the same in the two situations. These observations suggest that the relationship within pairs of @entity7533 is slightly modified by the birth of @entity1 and indicates that males and females could be using different strategies to enhance their reproductive success.

title: The effect of parturition on the interactions within pairs of XXXX ( @entity7533 ).

entities_list: @entity7533 :: ('9483', 'Species') :: ['Callithrix jacchus', 'common marmosets', 'common marmoset']

entities_list: @entity13635 :: ('MESH:C537238', 'Disease') :: ['heterosexual pairs']

answer: @entity7533 :: (9483,Species) :: ['common marmosets']


abstract: The relationship within @entity7533 ( @entity7533 ) pairs is based on pair-bond formation. This pair-bond is important for the successful rearing of the young and for the enhancement of reproductive success. Female marmosets bear twins which are carried mainly by males starting on the first day after the birth of the @entity1 . Little is known, however, about the patterns of sociosexual interaction between callitrichid pairs and how these interactions change after the arrival of offspring. To evaluate the effect of parturition on these interactions, three @entity13635 of @entity7533 were observed for four weeks before and four weeks after the birth of @entity1 . The animals were kept in individual outdoor cages of the Nucleo de Primatologia, under environmental conditions. The time spent in proximity was mainly attributable to the initiative of females before parturition and the initiative of males after the offspring arrived. Males were groomed more before than after the birth of @entity1 . In contrast, the amount of grooming received by females was the same in the two situations. These observations suggest that the relationship within pairs of @entity7533 is slightly modified by the birth of @entity1 and indicates that males and females could be using different strategies to enhance their reproductive success.

title: The effect of parturition on the interactions within pairs of @entity7533 ( XXXX ).

answer: @entity7533 :: (9483,Species) :: ['Callithrix jacchus']


abstract: Adequate @entity1760 ( @entity4612 ) levels play a vital role in membrane excitability, cell contractility and metabolism, being a key nutrient for sustaining appropriate muscular contraction and performance levels in athletes. Phase angle (PhA), assessed by bioimpedance analysis (BIA), has been reported to be positively associated with most nutritional markers and is an indicator of membrane integrity and water distribution between intra- and extracellular spaces. The aim of the present study was to verify the association between @entity4612 status and PhA as a predictor of cellular health, in a sample of judo athletes from a period of weight stability to prior to competition. Judo athletes (n  =  20) from the national team were evaluated on two occasions: during a period when body weight was stable (M1), and prior to competition (M2). Changes between these occasions were calculated as M2-M1. PhA was obtained by bioelectrical impedance spectroscopy at a frequency of 50 KHz. @entity4612 was measured in serum and red blood cells (RBC) by atomic absorption spectrophotometry, and @entity4612 in the diet was assessed from a 24-h diet record over a seven-day period, after an assessment of body composition. Mean PhA did not differ from M1 to M2. However, individual changes in PhA were positively associated with individual changes in serum (r  =  0.62, p  =  0.004) and RBC @entity4612 (r  =  0.45, p  =  0.048). This association was independent of weight changes between assessments, but when adjusted for @entity4612 intake changes, only the association between PhA and serum @entity4612 remained significant. These results highlight that in elite athletes PhA may be an indirect indicator of muscular function.

title: XXXX and phase angle: a prognostic tool for monitoring cellular integrity in judo athletes.

entities_list: @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']

answer: @entity1760 :: (MESH:D008274,Chemical) :: ['Magnesium']


abstract: @entity7736 is a @entity2927 caused by @entity8072 that usually attacks mammals, such as @entity1237 , @entity742 and @entity291 . The parasites can infect @entity1 via freshwater plants contaminated with encysted metacercariae. In the acute phase, which involves @entity99 , the disease may present with @entity490 , mild @entity221 and @entity382 . In the chronic phase, the parasites settle into the biliary tracts, and then cause @entity255 and @entity1448 . Sometimes, the disease may mimic @entity5 , creating a mass appearance. Endoscopic retrograde cholangiopancreatography (ERCP) is an important diagnostic and treatment method because it allows simultaneous diagnosis and treatment. Here, we present a 44-year-old female @entity1 who presented to our hospital with complaints of @entity490 , @entity390 , @entity391 , @entity448 and @entity353 . After diagnostic investigations with laboratory and imaging methods, she was initially hospitalized with a preliminary diagnosis of @entity201 ( @entity201 ). However, after a full work-up, the @entity1 was diagnosed with @entity8072 via ERCP and parasites were extracted with ERCP at the same time and then treated with a single dose of @entity31867 10 mg/kg. Two months later, the clinical status of the @entity1 had improved markedly, with resolution of all symptoms and all laboratory and imaging tests returning to within normal limits.

title: An incidental case of XXXX mimicking @entity201 .

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'patient']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity31867 :: ('MESH:C039276', 'Chemical') :: ['triclabendazole']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity2927 :: ('MESH:D015047', 'Disease') :: ['zoonotic infestation']

entities_list: @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia']

entities_list: @entity1448 :: ('MESH:D002779', 'Disease') :: ['cholestasis']

entities_list: @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']

entities_list: @entity201 :: ('MESH:D018281', 'Disease') :: ['CCC', 'cholangiocellular carcinoma']

entities_list: @entity8072 :: ('6192', 'Species') :: ['Fasciola hepatica']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity382 :: ('MESH:D006529', 'Disease') :: ['hepatomegaly']

entities_list: @entity7736 :: ('MESH:D005211', 'Disease') :: ['Fascioliasis']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic invasion']

answer: @entity7736 :: (MESH:D005211,Disease) :: ['biliary fascioliasis']


abstract: @entity7736 is a @entity2927 caused by @entity8072 that usually attacks mammals, such as @entity1237 , @entity742 and @entity291 . The parasites can infect @entity1 via freshwater plants contaminated with encysted metacercariae. In the acute phase, which involves @entity99 , the disease may present with @entity490 , mild @entity221 and @entity382 . In the chronic phase, the parasites settle into the biliary tracts, and then cause @entity255 and @entity1448 . Sometimes, the disease may mimic @entity5 , creating a mass appearance. Endoscopic retrograde cholangiopancreatography (ERCP) is an important diagnostic and treatment method because it allows simultaneous diagnosis and treatment. Here, we present a 44-year-old female @entity1 who presented to our hospital with complaints of @entity490 , @entity390 , @entity391 , @entity448 and @entity353 . After diagnostic investigations with laboratory and imaging methods, she was initially hospitalized with a preliminary diagnosis of @entity201 ( @entity201 ). However, after a full work-up, the @entity1 was diagnosed with @entity8072 via ERCP and parasites were extracted with ERCP at the same time and then treated with a single dose of @entity31867 10 mg/kg. Two months later, the clinical status of the @entity1 had improved markedly, with resolution of all symptoms and all laboratory and imaging tests returning to within normal limits.

title: An incidental case of @entity7736 mimicking XXXX .

answer: @entity201 :: (MESH:D018281,Disease) :: ['cholangiocellular carcinoma']


abstract: The construction of a transcriptional map for @entity1 chromosome 21 requires the generation of a specific catalogue of genes, together with corresponding mapping information. Towards this goal, we conducted a pilot study on a pool of random chromosome 21 cosmids representing 2 Mb of non-contiguous DNA. Exon-amplification and cDNA selection methods were used in combination to extract the coding content from these cosmids, and to derive expressed sequences libraries. These libraries and the source cosmid library were arrayed at high density for hybridisation screening. A strategy was used which related data obtained by multiple hybridisations of clones originating from one library, screened against the other libraries. In this way, it was possible to integrate the information with the physical map and to compare the gene recovery rate of each technique. cDNAs and exons were grouped into bins delineated by EcoRI cosmid fragments, and a subset of 91 cDNAs and 29 exons have been sequenced. These sequences defined 79 non-overlapping potential coding segments distributed in 24 transcriptional units, which were mapped along 21q. Northern blot analysis performed for a subset of cDNAs indicated the existence of a cognate transcript. Comparison to databases indicated three segments matching to known chromosome 21 genes: @entity49745 , @entity16583 and @entity4483 and six segments matching to unmapped anonymous expressed sequence tags (ESTs). At the translated @entity377 level, strong homologies to known proteins were found with @entity855 -binding transporters of the ABC family and the dihydroorotase domain of @entity7391 synthetases. These data strongly suggest that bona fide partial genes have been isolated. Several of the newly isolated transcriptional units map to clinically important regions, in particular those involved in @entity1467 , progressive @entity2045 and @entity1200 . The study presented here illustrates the complementarity of exon-amplification and cDNA selection techniques for generating a large resource of new expressed landmarks, which contribute to the construction of a chromosome 21 transcript map.

title: Model for a transcript map of XXXX chromosome 21: isolation of new coding sequences from exon and enriched cDNA libraries.

entities_list: @entity2045 :: ('MESH:D009207', 'Disease') :: ['myoclonus epilepsia']

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

entities_list: @entity1200 :: ('MESH:D007154', 'Disease') :: ['auto-immune polyglandular disease']

entities_list: @entity1467 :: ('MESH:D004314', 'Disease') :: ["Down's syndrome"]

entities_list: @entity7391 :: ('MESH:C030986', 'Chemical') :: ['pyrimidine']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND:    Acute @entity5924 frequently causes @entity1 hospitalization. Studies on different viruses or viral genomic load and disease severity or treatment effect have had conflicting results. We aimed to investigate whether the presence or concentration of individual or multiple viruses were associated with disease severity in @entity697 and to evaluate whether detected viruses modified the response to inhaled racemic @entity1425 . METHODS:    Nasopharyngeal aspirates were collected from 363 @entity1 with @entity697 in a randomized, controlled trial that compared inhaled racemic @entity1425 versus saline. Virus genome was identified and quantified by polymerase chain reaction analyses. Severity was assessed on the basis of the length of stay and the use of supportive care. RESULTS:    @entity10201 (83%) and @entity1 rhinovirus (34%) were most commonly detected. Seven other viruses were present in 8%-15% of the @entity1 . Two or more viruses (maximum, 7) were detected in 61% of the @entity1 . @entity778 was not associated with disease severity. A high genomic load of @entity10201 was associated with a longer length of stay and with an increased frequency of @entity26 and ventilatory support use. Treatment effect of inhaled @entity1425 was not modified by virus type, load or @entity325 . DISCUSSION:    In @entity1 hospitalized with @entity697 , disease severity was not associated with specific viruses or the total number of viruses detected. A high @entity5842 genomic load was associated with more-severe disease. CLINICAL TRIALS REGISTRATION:    NCT00817466 and EudraCT 2009-012667-34.

title: Virus Type and Genomic Load in Acute XXXX : Severity and Treatment Response With Inhaled @entity1425 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'infants', 'infant']

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['Virus type or coinfection']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['acute bronchiolitis']

entities_list: @entity10201 :: ('12814', 'Species') :: ['Respiratory syncytial virus', 'respiratory syncytial virus']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['adrenaline']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity5924 :: ('MESH:D001988', 'Disease') :: ['bronchiolitis']

entities_list: @entity325 :: ('MESH:D060085', 'Disease') :: ['coinfection']

answer: @entity5924 :: (MESH:D001988,Disease) :: ['Bronchiolitis']


abstract: BACKGROUND:    Acute @entity5924 frequently causes @entity1 hospitalization. Studies on different viruses or viral genomic load and disease severity or treatment effect have had conflicting results. We aimed to investigate whether the presence or concentration of individual or multiple viruses were associated with disease severity in @entity697 and to evaluate whether detected viruses modified the response to inhaled racemic @entity1425 . METHODS:    Nasopharyngeal aspirates were collected from 363 @entity1 with @entity697 in a randomized, controlled trial that compared inhaled racemic @entity1425 versus saline. Virus genome was identified and quantified by polymerase chain reaction analyses. Severity was assessed on the basis of the length of stay and the use of supportive care. RESULTS:    @entity10201 (83%) and @entity1 rhinovirus (34%) were most commonly detected. Seven other viruses were present in 8%-15% of the @entity1 . Two or more viruses (maximum, 7) were detected in 61% of the @entity1 . @entity778 was not associated with disease severity. A high genomic load of @entity10201 was associated with a longer length of stay and with an increased frequency of @entity26 and ventilatory support use. Treatment effect of inhaled @entity1425 was not modified by virus type, load or @entity325 . DISCUSSION:    In @entity1 hospitalized with @entity697 , disease severity was not associated with specific viruses or the total number of viruses detected. A high @entity5842 genomic load was associated with more-severe disease. CLINICAL TRIALS REGISTRATION:    NCT00817466 and EudraCT 2009-012667-34.

title: Virus Type and Genomic Load in Acute @entity5924 : Severity and Treatment Response With Inhaled XXXX .

answer: @entity1425 :: (MESH:D004837,Chemical) :: ['Adrenaline']


abstract: OBJECTIVES: The multidisciplinary clinic (MDC) has become the standard of care for individuals with @entity746 ( @entity746 ) in the United States, yet many @entity1 choose not to receive care at MDCs. We undertook a qualitative study of individuals with @entity746 to explore @entity1 ' perceptions of this form of service delivery. METHODS: @entity1 completed an online survey that posed open-ended questions about their attitudes and behaviors surrounding MCDs. Qualitative analysis was performed whereby response data was evaluated and grouped into themes. RESULTS: The unique aspect of MDCs most commonly cited by @entity1 was integrated care. Other reasons for attending MDC included those common to specialist centers, such as expertise, access to clinical trials, and participation in research. Perceived disadvantages unique to the MDC model were long and tiring visits. In common with many specialist centers, long travel times were cited as a disadvantage of MDCs. CONCLUSIONS: This information provides a foundation for improving @entity746 care. For those able to travel, the MDC model has much to offer, but @entity1 ' time should be respected. For those @entity1 who cannot travel, alternative models of care should be devised to provide integrated care, clinical expertise, and access to research.

title: A Qualitative Study of XXXX Clinic Use in the United States.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Participants']

entities_list: @entity746 :: ('MESH:D000690', 'Disease') :: ['amyotrophic lateral sclerosis', 'ALS']

answer: @entity746 :: (MESH:D000690,Disease) :: ['Multidisciplinary ALS']


abstract: AIMS: Calcific @entity472 ( @entity472 ) is purportedly associated with less @entity460 burden in @entity1 than in @entity1 . We sought to examine sex-related differences and correlates of surgically excised aortic valve weight (AVW) in pure @entity472 . METHODS AND RESULTS: Clinical and echocardiographic characteristics of 888 consecutive @entity1 who underwent aortic valve replacement for severe @entity472 were correlated to AVW, and in 126 @entity1 , AVW was also correlated to computed tomography aortic valve @entity460 (AVC) score. @entity1 and @entity1 had similar indexed valve area (0.42    0.09 vs. 0.42    0.07 cm (2)/m(2), P = 0.95) and mean systolic gradient (53    15 vs. 52    13 mmHg, P = 0.11), but @entity1 had higher New York Heart Association class (2.63    0.70 vs. 2.50    0.70, P = 0.01) and less prevalent @entity453 (38 vs. 52%, P < 0.0001). Aortic valve weight was lower in @entity1 (1.94    0.88 vs. 3.08    1.32 g, P < 0.0001) even when indexed to body surface area (1.09    0.48 vs. 1.48    0.62 g/m(2), P < 0.0001) or left ventricular outflow tract (LVOT) area (0.54    0.23 vs. 0.71    0.29 g/cm(2), P < 0.0001). Using multivariate analysis, male sex (P < 0.0001), bicuspid valve (P < 0.0001), and larger LVOT area (P < 0.0001) were the major determinants of increased AVW, along with current cigarette smoking (P = 0.007). @entity6 (P = 0.004) and @entity101 (P = 0.03) were independently associated with lower AVW. Aortic valve @entity460 correlated well with AVW (r = 0.81, P < 0.0001) and was lower in @entity1 than in @entity1 (2520    1199 vs. 3606    1632 arbitrary units, P < 0.0001). CONCLUSIONS: Despite the same degree of @entity472 severity, @entity1 have less AVC and lower AVW compared with @entity1 , irrespective of valve morphology. Aortic valve @entity460 is correlated to excised AVW. @entity101 , @entity6 , and current cigarette smoking were independently associated with AVW.

title: Sex-related differences in calcific aortic stenosis: correlating clinical and echocardiographic characteristics and computed tomography aortic valve XXXX score to excised aortic valve weight.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women', 'men']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'Hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['AS', 'aortic valve stenosis']

answer: @entity460 :: (MESH:D002118,Chemical) :: ['calcium']


abstract: AIMS: The right ventricle (RV) remodels early after @entity338 ( @entity338 ) in @entity215 ( @entity215 ) @entity1 . Previously reported preoperative thresholds to achieve early postoperative RV normalization were consistently close to 80 mL/m(2) for end-systolic volume ( @entity5778 ) and 160 mL/m(2) for end-diastolic volume (EDV). Our objective was to determine whether these thresholds were also associated with mid-to-late RV normalization and clinical events. METHODS AND RESULTS: Out of a multicentre cohort of 157 @entity215 @entity1 who had undergone @entity338 , in 65 @entity1 (62% male, age 29    8 years, homograft in 98%) cardiovascular magnetic resonance (CMR) imaging was performed preoperatively and >3 years (6.3 years, interquartile range: 4.9-9.5) postoperatively. Mid-to-late haemodynamic outcome was classified as: 'RV normalization' [RV ejection fraction (EF) > 48% and RV EDV < 108 mL/m(2)] in 14 of 65 (22%) @entity1 , 'intermediate' in 34 of 65 (52%) @entity1 , and 'suboptimal' (RV EF < 45% and RV EDV > 120 mL/m(2)) in 17 of 65 (26%) @entity1 . Preoperative RV @entity5778 < 80 mL/m(2) was strongly associated with favourable mid-to-late haemodynamic outcome in a proportional odds model [common odds ratio (OR): 0.04 for worse class, 95% confidence interval (CI): 0.01-0.17]. During 7.8    4.0 years follow-up after @entity338 , adverse clinical events ( @entity204 , sustained @entity1165 , or @entity712 ) occurred in 18 of 106 (17%) @entity1 with preoperative CMR available. @entity1 with preoperative RV @entity5778 > 95 mL/m(2) were at increased risk for unfavourable mid-to-late haemodynamic outcome (common OR: 25.5, 95% CI: 5.35-122) and events (hazard ratio: 2.89, 95% CI: 1.03-8.11). CONCLUSION: In @entity215 @entity1 who had undergone @entity338 , the best preoperative threshold to achieve mid-to-late RV normalization was RV @entity5778 < 80 mL/m(2). @entity1 with preoperative RV @entity5778 > 95 mL/m(2) were at increased risk for suboptimal haemodynamic outcome and adverse clinical events. Our findings may assist in timing of @entity338 .

title: Preoperative thresholds for mid-to-late haemodynamic and clinical outcomes after @entity338 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity215 :: ('MESH:D013771', 'Disease') :: ['TOF', 'tetralogy of Fallot']

entities_list: @entity338 :: ('MESH:D011665', 'Disease') :: ['PVR', 'pulmonary valve replacement']

answer: @entity215 :: (MESH:D013771,Disease) :: ['tetralogy of Fallot']


abstract: AIMS: The right ventricle (RV) remodels early after @entity338 ( @entity338 ) in @entity215 ( @entity215 ) @entity1 . Previously reported preoperative thresholds to achieve early postoperative RV normalization were consistently close to 80 mL/m(2) for end-systolic volume ( @entity5778 ) and 160 mL/m(2) for end-diastolic volume (EDV). Our objective was to determine whether these thresholds were also associated with mid-to-late RV normalization and clinical events. METHODS AND RESULTS: Out of a multicentre cohort of 157 @entity215 @entity1 who had undergone @entity338 , in 65 @entity1 (62% male, age 29    8 years, homograft in 98%) cardiovascular magnetic resonance (CMR) imaging was performed preoperatively and >3 years (6.3 years, interquartile range: 4.9-9.5) postoperatively. Mid-to-late haemodynamic outcome was classified as: 'RV normalization' [RV ejection fraction (EF) > 48% and RV EDV < 108 mL/m(2)] in 14 of 65 (22%) @entity1 , 'intermediate' in 34 of 65 (52%) @entity1 , and 'suboptimal' (RV EF < 45% and RV EDV > 120 mL/m(2)) in 17 of 65 (26%) @entity1 . Preoperative RV @entity5778 < 80 mL/m(2) was strongly associated with favourable mid-to-late haemodynamic outcome in a proportional odds model [common odds ratio (OR): 0.04 for worse class, 95% confidence interval (CI): 0.01-0.17]. During 7.8    4.0 years follow-up after @entity338 , adverse clinical events ( @entity204 , sustained @entity1165 , or @entity712 ) occurred in 18 of 106 (17%) @entity1 with preoperative CMR available. @entity1 with preoperative RV @entity5778 > 95 mL/m(2) were at increased risk for unfavourable mid-to-late haemodynamic outcome (common OR: 25.5, 95% CI: 5.35-122) and events (hazard ratio: 2.89, 95% CI: 1.03-8.11). CONCLUSION: In @entity215 @entity1 who had undergone @entity338 , the best preoperative threshold to achieve mid-to-late RV normalization was RV @entity5778 < 80 mL/m(2). @entity1 with preoperative RV @entity5778 > 95 mL/m(2) were at increased risk for suboptimal haemodynamic outcome and adverse clinical events. Our findings may assist in timing of @entity338 .

title: Preoperative thresholds for mid-to-late haemodynamic and clinical outcomes after XXXX in @entity215 .

answer: @entity338 :: (MESH:D011665,Disease) :: ['pulmonary valve replacement']


abstract: BACKGROUND AND PURPOSE: Administering postoperative radiotherapy (PORT) is associated with improved survival and slower disease progression in select @entity135 @entity1 . Predictive factors for PORT refusal have not been described in this population. MATERIALS AND METHODS: Retrospective analysis of 6127 @entity135 @entity1 who received or refused PORT in the National @entity5 Database (2003-2006) was performed. Statistical analysis included Chi-square, multivariable logistic regression, Kaplan-Meier, and Cox proportional hazards analysis. RESULTS: In total, 247 @entity1 (4.0%) refused PORT. Three-year overall survival was 62.8% versus 53.4% for those who received and refused PORT, respectively. PORT refusers were more likely to have negative nodes than those who underwent PORT (37.4% versus 20.1%, p<.001). In multivariate analysis, predictive factors for refusing PORT included living far from the treatment facility (OR 1.92), having negative nodes (OR 2.14), and Charlson score of    2 (OR 2.14) (all p   .001). PORT refusal was associated with increased mortality (hazard ratio 1.20, p=.044). CONCLUSIONS: A significant proportion of @entity135 @entity1 refused PORT; this was associated with compromised overall survival. Predictive factors for PORT refusal included socioeconomic, demographic, and pathologic variables. Elucidating root causes of refusal may lead to interventions that improve long-term outcomes.

title: Refusal of postoperative radiotherapy and its association with survival in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

answer: @entity135 :: (MESH:D006258,Disease) :: ['head and neck cancer']


abstract: BACKGROUND _ AIMS: Ghrelin is a gastric hormone circulating in acylated (AG) and unacylated (UG) forms, and higher plasma @entity348 ( @entity348 ) and UG may be cross-sectionally associated with lower @entity2690 resistance in @entity209 @entity1 . The potential value of ghrelin forms in predicting @entity2690 resistance and its time-related changes in community-based population cohorts remains unknown. METHODS: We measured @entity348 , AG and calculated UG ( @entity348 -AG) in 716 individuals from the North-East-Italy MoMa study (age: 55      9 years, BMI: 29      5  kg/m(2), M/F:349/367) to test the hypothesis that circulating @entity348 and UG, but not AG are negatively associated with @entity2690 resistance (HOMA). We further hypothesized that baseline @entity348 and UG negatively predict 5-year HOMA changes in a 350-individual subgroup. RESULTS: Baseline @entity348 and UG were associated negatively with HOMA after adjusting for gender and body mass index (BMI). Baseline gender- and BMI-adjusted @entity348 and UG were also negatively associated with HOMA at 5-year follow-up (n  =  350), and changes in @entity348 and UG were negatively associated with changes in HOMA (P  <  0.05) after adjustment for anthropometric and metabolic confounders. No statistically significant correlations were observed between AG and baseline or 5-year HOMA. CONCLUSIONS: In a North-East Italy community-based population cohort, plasma @entity348 and UG but not AG are negatively associated with HOMA. @entity348 and UG and their changes also independently predict 5-year HOMA changes. @entity348 and UG are therefore novel potential modulators of @entity2690 resistance and may contribute to predict its time-related changes in @entity1 .

title: Plasma total and unacylated ghrelin predict 5-year changes in XXXX resistance.

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome']

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'patients']

entities_list: @entity348 :: ('MESH:C535338', 'Disease') :: ['total ghrelin', 'TG']

answer: @entity2690 :: (3630,Gene) :: ['insulin']


abstract: IMPORTANCE: Detecting progression of @entity16 is often challenging. OBJECTIVE: To test the feasibility of using frequency-domain optical coherence tomography (FD-OCT) and a region-of-interest (ROI) approach to measure progressive changes in @entity16 . DESIGN, SETTING, AND @entity1 : Among a group of @entity1 in an institutional @entity726 practice who were likely to show @entity726 progression, eyes with a history of an @entity548 ( @entity548 ) confirmed by stereophotography were followed up with FD-OCT cube scans of the optic disc. All @entity1 underwent FD-OCT scans on at least 2 occasions separated by at least 1 year (mean, 3.45 years; range, 1.42-6.39 years). Because we were not studying the effects of an optic @entity548 , no constraint was placed on the time between the documentation of an optic @entity548 and the first scan used in the analysis. MAIN OUTCOMES AND MEASURES: After en face images of the FD-OCT scan were aligned based on the blood vessels, circumpapillary images were derived for an annulus 100   m in width, and the retinal nerve fiber layer (RNFL) thickness profiles were plotted for the first and last visits. The ROI width associated with the optic @entity548 was defined as the region of the RNFL profile below the 1% CI based on healthy norms. The change in the ROI width was compared with the change in the global RNFL thickness, which was obtained by averaging the circumpapillary RNFL thickness. RESULTS: The change in the ROI width (mean [SD], 8.0   [6.4  ]; 95% CI, 4.9   to 11.1  ; range, -0.7   to 19.3  ) was significant (P   <   .001, 2-tailed t test) while the change in the global thickness (mean [SD], 2.40 [5.87]  m; 95% CI, -0.48 to 5.28  m) was not significant (P   >   .12, 2-tailed t test). Although 15 of the 16 ROIs increased in width between visits, only 11 showed a decrease in the global RNFL thickness. CONCLUSIONS AND RELEVANCE: For detecting progression of local RNFL damage in @entity1 with @entity726 , an OCT ROI approach appears superior to the OCT global RNFL thickness measure typically used.

title: A Region-of-Interest Approach for Detecting Progression of XXXX With Optical Coherence Tomography.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['glaucomatous damage']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['DH', 'optic disc hemorrhage']

answer: @entity16 :: (MESH:D009422,Disease) :: ['Glaucomatous Damage']


abstract: OBJECTIVES/HYPOTHESIS: To evaluate the short-term voice outcomes of vocal fold augmentation using fat compared to calcium hydroxylapatite product Radiesse Voice (Merz Aesthetics). STUDY DESIGN: Retrospective study design. METHODS: Sixty-six consecutive @entity1 with @entity3746 were recruited, including the final 33 @entity1 treated with fat and all 33 @entity1 treated with calcium hydroxylapatite product. Before April 2011, fat augmentation was the standard treatment; from April 2011, only @entity460 hydroxylapatite product was used. For all subjects, videolaryngostroboscopic evaluation, s/z ratios, and @entity1032 index (VHI) were analyzed. METHODS: Treatment outcomes were evaluated 3 months after the augmentation. Two @entity1 augmented with fat (both after 6 months), versus four augmented with @entity460 hydroxylapatite product (mean after 7 months), needed reintervention. Mean VHI decreased from 18 points in the fat augmentation group compared to 17 points in the @entity460 hydroxylapatite group. Mean s/z ratio changed -0.33 in the fat augmentation group compared to -0.46 in the @entity460 hydroxylapatite group. CONCLUSION: This retrospective cohort demonstrates that there are no short-term differences in VHI outcome or number of reinterventions for augmentation with fat compared to calcium hydroxylapatite product Radiesse Voice (Merz Aesthetics). LEVEL OF EVIDENCE: Level 4. Laryngoscope, 2014.

title: Comparison of voice outcome after vocal fold augmentation with fat or XXXX hydroxylapatite.

entities_list: @entity3746 :: ('MESH:D014826', 'Disease') :: ['vocal fold insufficiency']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['voice handicap']

answer: @entity460 :: (MESH:D002118,Chemical) :: ['calcium']


abstract: The ability of small @entity4360 -positive (SACHE) cells to incorporate tritiated @entity1014 ( @entity665 ) was studied in the bone marrow of @entity19 made acutely @entity882 by injection of guinea pig antimouse platelet serum (APS) and in control @entity19 injected with normal guinea pig serum (NS). @entity665 was administered in vivo, and bone marrow was collected at various time points thereafter. The initial @entity894 ( @entity894 ) for both groups was about 30%. After four hours, the @entity894 increased and reached peak values at 48 hours, but was lower in @entity882 animals. The lower peak @entity894 in APS-treated animals may be the result of both a faster rate of influx of unlabeled cells into the @entity4360 ( @entity4360 ) positive cell compartment and efflux of more heavily labeled, and probably polyploid, SACHE cells into the compartment of recognizable megakaryocytes. In both groups the increasing @entity894 occurred concomitantly with a decreasing mean grain count. This may indicate cellular division by some fraction of SACHE cells. Heterogeneity in nuclear morphology was also demonstrated, and the frequency of individual morphologies was altered in APS-treated animals. In addition, cells that incorporated @entity665 were larger than those that did not. This group of small cells appears to represent a pivotal point in megakaryocytopoiesis in which the switch from mitosis to endomitosis is occurring.

title: Megakaryocytopoiesis: incorporation of tritiated @entity1014 by small XXXX -positive cells in @entity19 bone marrow during antibody-induced @entity882 .

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenic']

entities_list: @entity894 :: ('MESH:C566784', 'Disease') :: ['labeling index', 'LI']

entities_list: @entity4360 :: ('11423(Tax:10090)', 'Gene') :: ['AChE', 'acetylcholinesterase']

entities_list: @entity1014 :: ('MESH:D013936', 'Chemical') :: ['thymidine']

answer: @entity4360 :: (11423(Tax:10090),Gene) :: ['acetylcholinesterase']


abstract: The ability of small @entity4360 -positive (SACHE) cells to incorporate tritiated @entity1014 ( @entity665 ) was studied in the bone marrow of @entity19 made acutely @entity882 by injection of guinea pig antimouse platelet serum (APS) and in control @entity19 injected with normal guinea pig serum (NS). @entity665 was administered in vivo, and bone marrow was collected at various time points thereafter. The initial @entity894 ( @entity894 ) for both groups was about 30%. After four hours, the @entity894 increased and reached peak values at 48 hours, but was lower in @entity882 animals. The lower peak @entity894 in APS-treated animals may be the result of both a faster rate of influx of unlabeled cells into the @entity4360 ( @entity4360 ) positive cell compartment and efflux of more heavily labeled, and probably polyploid, SACHE cells into the compartment of recognizable megakaryocytes. In both groups the increasing @entity894 occurred concomitantly with a decreasing mean grain count. This may indicate cellular division by some fraction of SACHE cells. Heterogeneity in nuclear morphology was also demonstrated, and the frequency of individual morphologies was altered in APS-treated animals. In addition, cells that incorporated @entity665 were larger than those that did not. This group of small cells appears to represent a pivotal point in megakaryocytopoiesis in which the switch from mitosis to endomitosis is occurring.

title: Megakaryocytopoiesis: incorporation of tritiated @entity1014 by small @entity4360 -positive cells in @entity19 bone marrow during antibody-induced XXXX .

answer: @entity882 :: (MESH:D013921,Disease) :: ['thrombocytopenia']


abstract: The ability of small @entity4360 -positive (SACHE) cells to incorporate tritiated @entity1014 ( @entity665 ) was studied in the bone marrow of @entity19 made acutely @entity882 by injection of guinea pig antimouse platelet serum (APS) and in control @entity19 injected with normal guinea pig serum (NS). @entity665 was administered in vivo, and bone marrow was collected at various time points thereafter. The initial @entity894 ( @entity894 ) for both groups was about 30%. After four hours, the @entity894 increased and reached peak values at 48 hours, but was lower in @entity882 animals. The lower peak @entity894 in APS-treated animals may be the result of both a faster rate of influx of unlabeled cells into the @entity4360 ( @entity4360 ) positive cell compartment and efflux of more heavily labeled, and probably polyploid, SACHE cells into the compartment of recognizable megakaryocytes. In both groups the increasing @entity894 occurred concomitantly with a decreasing mean grain count. This may indicate cellular division by some fraction of SACHE cells. Heterogeneity in nuclear morphology was also demonstrated, and the frequency of individual morphologies was altered in APS-treated animals. In addition, cells that incorporated @entity665 were larger than those that did not. This group of small cells appears to represent a pivotal point in megakaryocytopoiesis in which the switch from mitosis to endomitosis is occurring.

title: Megakaryocytopoiesis: incorporation of tritiated XXXX by small @entity4360 -positive cells in @entity19 bone marrow during antibody-induced @entity882 .

answer: @entity1014 :: (MESH:D013936,Chemical) :: ['thymidine']


abstract: The ability of small @entity4360 -positive (SACHE) cells to incorporate tritiated @entity1014 ( @entity665 ) was studied in the bone marrow of @entity19 made acutely @entity882 by injection of guinea pig antimouse platelet serum (APS) and in control @entity19 injected with normal guinea pig serum (NS). @entity665 was administered in vivo, and bone marrow was collected at various time points thereafter. The initial @entity894 ( @entity894 ) for both groups was about 30%. After four hours, the @entity894 increased and reached peak values at 48 hours, but was lower in @entity882 animals. The lower peak @entity894 in APS-treated animals may be the result of both a faster rate of influx of unlabeled cells into the @entity4360 ( @entity4360 ) positive cell compartment and efflux of more heavily labeled, and probably polyploid, SACHE cells into the compartment of recognizable megakaryocytes. In both groups the increasing @entity894 occurred concomitantly with a decreasing mean grain count. This may indicate cellular division by some fraction of SACHE cells. Heterogeneity in nuclear morphology was also demonstrated, and the frequency of individual morphologies was altered in APS-treated animals. In addition, cells that incorporated @entity665 were larger than those that did not. This group of small cells appears to represent a pivotal point in megakaryocytopoiesis in which the switch from mitosis to endomitosis is occurring.

title: Megakaryocytopoiesis: incorporation of tritiated @entity1014 by small @entity4360 -positive cells in XXXX bone marrow during antibody-induced @entity882 .

answer: @entity19 :: (10090,Species) :: ['murine']


abstract: OBJECTIVE: To investigate the effect of serum @entity53 (E2) levels on the day of @entity1 chorionic gonadotropin ( @entity1465 ) administration on the outcome of controlled @entity43 (COH) in both long @entity4396 ( @entity1176 ) agonist and @entity1176 antagonist protocols. MATERIALS AND METHODS: This study included 212 in vitro fertilization-embryo transfer (IVF-ET) cycles performed with either long @entity1176 agonist or @entity1176 antagonist protocols were classified into three groups according to serum E2 levels measured on the day of @entity1465 injection: < 2,000 pg/ml, 2,000-4,000 pg/ml, and > 4,000 pg/ml. The three groups were compared according to age, number of retrieved oocytes, number of transferred embryos, and pregnancy rates for each of the stimulation protocols. RESULTS: The long and antagonist protocols were performed in 130 and 82 cycles, respectively. The pregnancy rates were 21.5% (28/130) and 23.2% (19/82) in the long- and antagonist-protocol groups, respectively. Serum E2 levels were measured on the day of @entity1465 administration as < 2,000 pg/ml in 65 cycles, 2,000-4,000 pg/ml in 76 cycles, and > 4,000 pg/ml in 71 cycles. The number of retrieved oocytes increased in parallel to serum E2 levels (p = 0.001). However, there was no significant difference among groups in the pregnancy rates (p = 0.116). Similarly, the number of retrieved oocytes increased in parallel to serum E2 levels in both of the protocol groups (p value was 0.001 in both long @entity1176 agonist and antagonist protocols), but there was no correlation between the pregnancy rates and serum E2 levels (p value of long @entity1176 agonist protocol was 0.254 and thep value of antagonist group was 0.349). CONCLUSION: The serum E2 level on the day of @entity1465 administration does not predict the pregnancy outcome in IVF with either long @entity1176 agonist or @entity1176 antagonist protocols.

title: Does the XXXX level on the day of @entity1 chorionic gonadotropin administration predict the clinical outcome of controlled @entity43 ?

entities_list: @entity4396 :: ('2796', 'Gene') :: ['gonadotropin-releasing hormone']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian hyperstimulation']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']

answer: @entity53 :: (MESH:D004958,Chemical) :: ['estradiol']


abstract: OBJECTIVE: To investigate the effect of serum @entity53 (E2) levels on the day of @entity1 chorionic gonadotropin ( @entity1465 ) administration on the outcome of controlled @entity43 (COH) in both long @entity4396 ( @entity1176 ) agonist and @entity1176 antagonist protocols. MATERIALS AND METHODS: This study included 212 in vitro fertilization-embryo transfer (IVF-ET) cycles performed with either long @entity1176 agonist or @entity1176 antagonist protocols were classified into three groups according to serum E2 levels measured on the day of @entity1465 injection: < 2,000 pg/ml, 2,000-4,000 pg/ml, and > 4,000 pg/ml. The three groups were compared according to age, number of retrieved oocytes, number of transferred embryos, and pregnancy rates for each of the stimulation protocols. RESULTS: The long and antagonist protocols were performed in 130 and 82 cycles, respectively. The pregnancy rates were 21.5% (28/130) and 23.2% (19/82) in the long- and antagonist-protocol groups, respectively. Serum E2 levels were measured on the day of @entity1465 administration as < 2,000 pg/ml in 65 cycles, 2,000-4,000 pg/ml in 76 cycles, and > 4,000 pg/ml in 71 cycles. The number of retrieved oocytes increased in parallel to serum E2 levels (p = 0.001). However, there was no significant difference among groups in the pregnancy rates (p = 0.116). Similarly, the number of retrieved oocytes increased in parallel to serum E2 levels in both of the protocol groups (p value was 0.001 in both long @entity1176 agonist and antagonist protocols), but there was no correlation between the pregnancy rates and serum E2 levels (p value of long @entity1176 agonist protocol was 0.254 and thep value of antagonist group was 0.349). CONCLUSION: The serum E2 level on the day of @entity1465 administration does not predict the pregnancy outcome in IVF with either long @entity1176 agonist or @entity1176 antagonist protocols.

title: Does the @entity53 level on the day of @entity1 chorionic gonadotropin administration predict the clinical outcome of controlled XXXX ?

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian hyperstimulation']


abstract: OBJECTIVE: To investigate the effect of serum @entity53 (E2) levels on the day of @entity1 chorionic gonadotropin ( @entity1465 ) administration on the outcome of controlled @entity43 (COH) in both long @entity4396 ( @entity1176 ) agonist and @entity1176 antagonist protocols. MATERIALS AND METHODS: This study included 212 in vitro fertilization-embryo transfer (IVF-ET) cycles performed with either long @entity1176 agonist or @entity1176 antagonist protocols were classified into three groups according to serum E2 levels measured on the day of @entity1465 injection: < 2,000 pg/ml, 2,000-4,000 pg/ml, and > 4,000 pg/ml. The three groups were compared according to age, number of retrieved oocytes, number of transferred embryos, and pregnancy rates for each of the stimulation protocols. RESULTS: The long and antagonist protocols were performed in 130 and 82 cycles, respectively. The pregnancy rates were 21.5% (28/130) and 23.2% (19/82) in the long- and antagonist-protocol groups, respectively. Serum E2 levels were measured on the day of @entity1465 administration as < 2,000 pg/ml in 65 cycles, 2,000-4,000 pg/ml in 76 cycles, and > 4,000 pg/ml in 71 cycles. The number of retrieved oocytes increased in parallel to serum E2 levels (p = 0.001). However, there was no significant difference among groups in the pregnancy rates (p = 0.116). Similarly, the number of retrieved oocytes increased in parallel to serum E2 levels in both of the protocol groups (p value was 0.001 in both long @entity1176 agonist and antagonist protocols), but there was no correlation between the pregnancy rates and serum E2 levels (p value of long @entity1176 agonist protocol was 0.254 and thep value of antagonist group was 0.349). CONCLUSION: The serum E2 level on the day of @entity1465 administration does not predict the pregnancy outcome in IVF with either long @entity1176 agonist or @entity1176 antagonist protocols.

title: Does the @entity53 level on the day of XXXX chorionic gonadotropin administration predict the clinical outcome of controlled @entity43 ?

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: To discuss the clinical significance of the @entity353 for femoral lesser trochanteric fragment in treating the femoral comminuted intertrochanteric @entity174 . METHODS: From January 2012 to December 2013,32 @entity1 with intertrochanteric @entity174 were treated by surgery, and self-designed reduction fixators were used in the @entity1 for the fixation of @entity2249 . There were 11 males and 21 females, ranging in age from 45 to 81 years old with an average of 64 years old. According to the Evans typing, 12 cases were type II, 13 cases were type III and 7 cases were type IV. Simple lag screw fixed in 19 cases and steel wire fixed in 13 cases. Hip joint function was evaluated according Harris score and the complications such as coxa adducta,cutting of femoral head and neck,implants breakage were observed. RESULTS: Thirty-two @entity1 were followed up from 9 to 24 months with an average of 13 months. Coxa adducta occurred in 1 case,no cutting of femoral head and neck occurred and implants breakage were found. The mean Harris score was 91.80    3.05 in 32 @entity1 . CONCLUSION: The reconstruction and fixation for the posterior medial bone cortex continuity is a key factor on affect the stability of femoral intertrochanteric @entity174 . Self-designed reduction fixators can effective reduce and fix the @entity2249 , it has advantage of fast @entity353 , and simple operation.

title: [Design of the reduction fixator and its clinical application in treating @entity174 of XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2249 :: ('MESH:D005265', 'Disease') :: ['lesser trochanter of femur']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['reduction and fixation']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture']

answer: @entity2249 :: (MESH:D005265,Disease) :: ['lesser trochanter of femur']


abstract: OBJECTIVE: To discuss the clinical significance of the @entity353 for femoral lesser trochanteric fragment in treating the femoral comminuted intertrochanteric @entity174 . METHODS: From January 2012 to December 2013,32 @entity1 with intertrochanteric @entity174 were treated by surgery, and self-designed reduction fixators were used in the @entity1 for the fixation of @entity2249 . There were 11 males and 21 females, ranging in age from 45 to 81 years old with an average of 64 years old. According to the Evans typing, 12 cases were type II, 13 cases were type III and 7 cases were type IV. Simple lag screw fixed in 19 cases and steel wire fixed in 13 cases. Hip joint function was evaluated according Harris score and the complications such as coxa adducta,cutting of femoral head and neck,implants breakage were observed. RESULTS: Thirty-two @entity1 were followed up from 9 to 24 months with an average of 13 months. Coxa adducta occurred in 1 case,no cutting of femoral head and neck occurred and implants breakage were found. The mean Harris score was 91.80    3.05 in 32 @entity1 . CONCLUSION: The reconstruction and fixation for the posterior medial bone cortex continuity is a key factor on affect the stability of femoral intertrochanteric @entity174 . Self-designed reduction fixators can effective reduce and fix the @entity2249 , it has advantage of fast @entity353 , and simple operation.

title: [Design of the reduction fixator and its clinical application in treating XXXX of @entity2249 ].

answer: @entity174 :: (MESH:D050723,Disease) :: ['fracture']


abstract: This study sought to characterize @entity1 with @entity5720 seen at one tertiary referral center by reviewing medical records of @entity1 with a confirmed diagnosis between January 1, 1976 and September 1, 1992. One hundred sixty-five cases were identified. The mean age at diagnosis was 57 yr (SD 15). The female-to-male ratio was 1.1:1.0. Ninety-two percent of @entity1 were white. Seventy-seven percent of cases were unsuspected before diagnosis, and 16% were diagnosed at autopsy. The most common associated conditions were @entity293 , analgesic abuse, @entity5450 , @entity6 , and @entity3458 . There was considerable overlap in the presence of these conditions, with two or more identified in 36% of @entity1 . In addition, 11% of @entity1 had none of these well-recognized risks. Other diagnoses in this group included @entity1988 , @entity2883 , and @entity2791 . A decline in case numbers of approximately 50% was demonstrated over the last 10 yr studied. This period was associated with a 57% reduction in the number of excretory urograms carried out, suggesting that changes in diagnostic imaging preference may have contributed. Vital status and renal outcome data after diagnosis were obtained in 93% of cases. Of those diagnosed while living, survival was lowest among @entity6 @entity1 . Ten-year survival for nondiabetics was not significantly different from the expected survival of an age- and sex-matched cohort. The overall risk for requiring renal replacement therapy after the diagnosis of @entity5720 in surviving @entity1 was low (7% of 136 @entity1 at risk).(ABSTRACT TRUNCATED AT 250 WORDS)

title: XXXX necrosis--a sixteen-year clinical experience.

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes mellitus']

entities_list: @entity5720 :: ('MESH:D007681', 'Disease') :: ['renal papillary necrosis']

entities_list: @entity5450 :: ('MESH:D014570', 'Disease') :: ['urinary tract obstruction']

entities_list: @entity3458 :: ('MESH:D000755', 'Disease') :: ['sickle cell disease']

entities_list: @entity2791 :: ('MESH:D012078', 'Disease') :: ['renal artery stenosis']

entities_list: @entity1988 :: ('MESH:D008181', 'Disease') :: ['lupus nephritis']

entities_list: @entity2883 :: ('MESH:D014890', 'Disease') :: ["Wegener's granulomatosis"]

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infection']

answer: @entity5720 :: (MESH:D007681,Disease) :: ['Renal papillary']


abstract: BACKGROUND: Percutaneous (minimally invasive) suturing is a promising option for @entity924 ( @entity924 ) repair with low rerupture and infection rates. @entity66 are the major problem to avoid with the technique. A new device was therefore designed for suturing the @entity924 , resulting in channel-assisted minimally invasive repair (CAMIR). The purpose of this study was to compare the clinical and functional outcomes of CAMIR with traditional open techniques. METHOD: Eighty two @entity1 with @entity397 were included: 41 for CAMIR, 41 for open repair. All @entity1 followed a standardized rehabilitation protocol. Follow-ups were at 12 and 24  months after surgery. Functional evaluation was based on the clinical American Orthopaedic Foot _ Ankle Society score associated with @entity51 (sural nerve), @entity291 circumference, range of motion (ROM), and isometric testing. RESULTS: There was no difference between groups regarding plantar flexor strength, ankle ROM, or @entity291 circumference. CAMIR significantly decreased the operative time compared to open repair (17 vs. 56  min, P   <   0.0001). Mean scar length was greater in the open repair group (10 vs. 2  cm, P   <   0.0001). There were no wound complications in the CAMIR group but four in the open repair group (P   <   0.0001). No @entity1150 , rerupture, or @entity128 occurred. CONCLUSION: CAMIR and open repair yielded essentially identical clinical and functional outcomes. @entity128 can be minimized using CAMIR by carefully placing the suture channel with a stab incision and special trocar based on a modified Bunnell suture technique.

title: Channel-assisted minimally invasive repair of acute XXXX .

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Sural nerve lesions']

entities_list: @entity924 :: ('MESH:D052256', 'Disease') :: ['Achilles tendon', 'AT']

entities_list: @entity128 :: ('MESH:D020209', 'Disease') :: ['sural nerve injury', 'Sural nerve injuries']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurologic deficit']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['AT rupture']

answer: @entity397 :: (MESH:D012421,Disease) :: ['Achilles tendon rupture']


abstract: OBJECTIVE: To report the type and prevalence of obstetric lacerations in a primigravid @entity1 population after term spontaneous vaginal delivery without episiotomy. We examined the characteristics of lacerations in @entity1 with postpartum @entity546 or @entity2411 . STUDY DESIGN: This was a retrospective cohort of primiparous @entity1 who spontaneously delivered in the residents' service at a large urban hospital under the supervision of Ob/Gyn faculty. Data was extracted from medical records using discharge diagnosis codes. Postpartum medical records and diagnostic codes of all @entity1 with lacerations and postpartum @entity546 were reviewed. The study was IRB approved. RESULTS: A cohort of 1617 primiparous @entity1 with spontaneous vaginal delivery met the inclusion criteria. No tears were recorded in 836 @entity1 (51.7%), first-degree tears in 413 cases (25.5%), second-degree tears in 271 cases (16.8%), third-degree tears in 58 cases (3.6%), fourth-degree in 21 cases (1.3%), and 18 cases (1.1%) were not further classified. Only 51 @entity1 (3.2%) with first- and second-degree lacerations had postpartum complications, and merely 6 (0.4%) had @entity158 and 6 (0.4%) had @entity546 . However, 4 of those @entity1 (33.3%) required vulvoplasty for @entity546 . CONCLUSION: Almost half of @entity1 with spontaneous vaginal delivery without episiotomy experienced some @entity4551 . A first degree was documented in >25% of cases; however, <10% of those subsequently had complaints of @entity158 or @entity546 .

title: XXXX and postpartum @entity546 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2411 :: ('MESH:D056650', 'Disease') :: ['vulvodynia']

entities_list: @entity4551 :: ('MESH:D022125', 'Disease') :: ['type of vaginal laceration']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['vulvar pain']

entities_list: @entity546 :: ('MESH:D004414', 'Disease') :: ['complete dyspareunia remission', 'dyspareunia']

answer: @entity4551 :: (MESH:D022125,Disease) :: ['Obstetric vulvar lacerations']


abstract: OBJECTIVE: To report the type and prevalence of obstetric lacerations in a primigravid @entity1 population after term spontaneous vaginal delivery without episiotomy. We examined the characteristics of lacerations in @entity1 with postpartum @entity546 or @entity2411 . STUDY DESIGN: This was a retrospective cohort of primiparous @entity1 who spontaneously delivered in the residents' service at a large urban hospital under the supervision of Ob/Gyn faculty. Data was extracted from medical records using discharge diagnosis codes. Postpartum medical records and diagnostic codes of all @entity1 with lacerations and postpartum @entity546 were reviewed. The study was IRB approved. RESULTS: A cohort of 1617 primiparous @entity1 with spontaneous vaginal delivery met the inclusion criteria. No tears were recorded in 836 @entity1 (51.7%), first-degree tears in 413 cases (25.5%), second-degree tears in 271 cases (16.8%), third-degree tears in 58 cases (3.6%), fourth-degree in 21 cases (1.3%), and 18 cases (1.1%) were not further classified. Only 51 @entity1 (3.2%) with first- and second-degree lacerations had postpartum complications, and merely 6 (0.4%) had @entity158 and 6 (0.4%) had @entity546 . However, 4 of those @entity1 (33.3%) required vulvoplasty for @entity546 . CONCLUSION: Almost half of @entity1 with spontaneous vaginal delivery without episiotomy experienced some @entity4551 . A first degree was documented in >25% of cases; however, <10% of those subsequently had complaints of @entity158 or @entity546 .

title: @entity4551 and postpartum XXXX .

answer: @entity546 :: (MESH:D004414,Disease) :: ['dyspareunia']


abstract: Twenty-four @entity1 aged 3 months to 18 years (median, 12 years) were treated for @entity6011 at the @entity1 's Hospital of Philadelphia Cancer Research Center from 1958 through 1984. Sixteen @entity1 had @entity4786 ( @entity4786 ). The @entity5 arose in an extremity or in the trunk (15 @entity1 ), the retroperitoneum-pelvis (6), or other sites (3). Twelve @entity1 underwent grossly complete excision of localized @entity242 ; of them, five had no known @entity41 and seven had proven microscopic @entity66 . Ten of the remaining 12 @entity1 had grossly visible, residual localized disease, and two had lung metastases. After operation, nine were treated on a protocol with local radiation therapy (4000-6000 rad) plus @entity1891 , @entity4316 , and @entity786 with or without @entity632 ( @entity632 ). The other 15 were treated variably. At 3 years, the proportion of @entity5 -free survivors was 9 of 24 (37.5%). The significant favorable factors were the initial surgical removal of all gross @entity5 (9 of 12 with @entity5 excision were @entity5 -free survivors at 3 years compared to none of 12 with gross residual @entity242 ; P less than 0.01), and a @entity5 mitotic rate under one per high-power field. No significant correlation was found between @entity5 -free survival expectancy and age, race, sex, the presence of @entity4786 , the site and size of the @entity5 , or use of the chemoradiotherapy regimen. More effective treatment programs are needed for @entity1 with @entity6011 , especially for those with unresectable @entity5 .

title: Treatment of @entity1 with XXXX . Experience at the @entity1 's Hospital of Philadelphia, 1958-1984.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['Adriamycin', 'doxorubicin']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease']

entities_list: @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumor', 'tumors']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity4316 :: ('MESH:D003609', 'Chemical') :: ['actinomycin D']

entities_list: @entity6011 :: ('MESH:D018319', 'Disease') :: ['neurogenic sarcoma']

entities_list: @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']

entities_list: @entity4786 :: ('MESH:D017253', 'Disease') :: ['NF', 'neurofibromatosis']

answer: @entity6011 :: (MESH:D018319,Disease) :: ['neurogenic sarcoma']


abstract: Twenty-four @entity1 aged 3 months to 18 years (median, 12 years) were treated for @entity6011 at the @entity1 's Hospital of Philadelphia Cancer Research Center from 1958 through 1984. Sixteen @entity1 had @entity4786 ( @entity4786 ). The @entity5 arose in an extremity or in the trunk (15 @entity1 ), the retroperitoneum-pelvis (6), or other sites (3). Twelve @entity1 underwent grossly complete excision of localized @entity242 ; of them, five had no known @entity41 and seven had proven microscopic @entity66 . Ten of the remaining 12 @entity1 had grossly visible, residual localized disease, and two had lung metastases. After operation, nine were treated on a protocol with local radiation therapy (4000-6000 rad) plus @entity1891 , @entity4316 , and @entity786 with or without @entity632 ( @entity632 ). The other 15 were treated variably. At 3 years, the proportion of @entity5 -free survivors was 9 of 24 (37.5%). The significant favorable factors were the initial surgical removal of all gross @entity5 (9 of 12 with @entity5 excision were @entity5 -free survivors at 3 years compared to none of 12 with gross residual @entity242 ; P less than 0.01), and a @entity5 mitotic rate under one per high-power field. No significant correlation was found between @entity5 -free survival expectancy and age, race, sex, the presence of @entity4786 , the site and size of the @entity5 , or use of the chemoradiotherapy regimen. More effective treatment programs are needed for @entity1 with @entity6011 , especially for those with unresectable @entity5 .

title: Treatment of XXXX with @entity6011 . Experience at the @entity1 's Hospital of Philadelphia, 1958-1984.

answer: @entity1 :: (9606,Species) :: ['children']


abstract: Twenty-four @entity1 aged 3 months to 18 years (median, 12 years) were treated for @entity6011 at the @entity1 's Hospital of Philadelphia Cancer Research Center from 1958 through 1984. Sixteen @entity1 had @entity4786 ( @entity4786 ). The @entity5 arose in an extremity or in the trunk (15 @entity1 ), the retroperitoneum-pelvis (6), or other sites (3). Twelve @entity1 underwent grossly complete excision of localized @entity242 ; of them, five had no known @entity41 and seven had proven microscopic @entity66 . Ten of the remaining 12 @entity1 had grossly visible, residual localized disease, and two had lung metastases. After operation, nine were treated on a protocol with local radiation therapy (4000-6000 rad) plus @entity1891 , @entity4316 , and @entity786 with or without @entity632 ( @entity632 ). The other 15 were treated variably. At 3 years, the proportion of @entity5 -free survivors was 9 of 24 (37.5%). The significant favorable factors were the initial surgical removal of all gross @entity5 (9 of 12 with @entity5 excision were @entity5 -free survivors at 3 years compared to none of 12 with gross residual @entity242 ; P less than 0.01), and a @entity5 mitotic rate under one per high-power field. No significant correlation was found between @entity5 -free survival expectancy and age, race, sex, the presence of @entity4786 , the site and size of the @entity5 , or use of the chemoradiotherapy regimen. More effective treatment programs are needed for @entity1 with @entity6011 , especially for those with unresectable @entity5 .

title: Treatment of @entity1 with @entity6011 . Experience at the XXXX 's Hospital of Philadelphia, 1958-1984.

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: More than 1000 cells of a spontaneously transformed line of BALB/3T3 cells are required to initiate @entity5 in half the @entity19 inoculated s.c., although the cells clone with an efficiency approaching 100% in culture. The cells of two @entity5 with prolonged latent periods, initiated by 2 X 10(4) and 5 X 10(3) cells, were chosen for detailed clonal analysis in culture. The cells from the @entity5 grew very poorly in culture in the first passages, but with increasing speed and efficiency in later passages. Cells derived directly from the two @entity5 cloned in agar with an efficiency of 0.01 and 0.002%. The growth rates on plastic of the rare successful clones derived from agar were generally low but extremely varied. Some clones lost the capacity for multiplication in a few passages, while others persisted but fluctuated unpredictably in growth rate in the early passages. The graded increase in growth rate of the uncloned @entity5 cell populations was probably the result of selection of the more rapidly growing clones. One of the slower-growing clones was subcloned. About half of the subclones grew at a slower rate than the parental clone. These, however, increased progressively in growth rate over six successive weekly passages, suggesting the occurrence of a gradual physiological adaptation. We conclude that selection of fast-growing clones contributes a major part of the gradually improving growth of @entity5 cell populations in culture, but that a physiological adaptation extending over many cell generations makes a significant contribution. The mechanism in either case is unknown, and indeed there may not be a unique mechanism in the scientifically rigorous sense.

title: Selection and adaptation for rapid growth in culture of cells from delayed sarcomas in XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

answer: @entity19 :: (10090,Species) :: ['nude mice']


abstract: Prior study of the combination of @entity19859 and high dose @entity2592 with @entity1261 ( @entity1261 ) priming (GCLAC) in relapsed or refractory @entity3052 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity3118 , @entity2592 , @entity1261 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity4434 ), and @entity137 of GCLAC. @entity19859 was administered at 30 mg m(-2) day(-1) * 5 and @entity2592 at 2 g m(-2) day(-1) * 5 after @entity1261 priming in 50 newly-diagnosed @entity1 ages 18-64 with @entity3052 or advanced @entity2590 ( @entity2590 ) or @entity1442 ( @entity5 ). Responses were assessed in the different cytogenetic risk groups and in @entity1 with @entity1503 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity1 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity1 with an @entity1503 ( @entity1503 ), the CR rate was 65%, compared to 85% for those without an @entity1503 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity3052 and advanced @entity9713 .

title: @entity1261 priming, XXXX , and high dose @entity2592 (GCLAC) for upfront treatment of @entity3052 , advanced @entity2590 or @entity1442 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte colony-stimulating factor']

entities_list: @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome', 'MDS']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML']

entities_list: @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine']

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced myeloproliferative neoplasm']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['AHD', 'antecedent hematologic disorder']

entities_list: @entity9713 :: ('MESH:D054437', 'Disease') :: ['myelodysplastic or myeloproliferative disorders']

entities_list: @entity19859 :: ('MESH:C068329', 'Chemical') :: ['Clofarabine', 'clofarabine']

answer: @entity19859 :: (MESH:C068329,Chemical) :: ['clofarabine']


abstract: Prior study of the combination of @entity19859 and high dose @entity2592 with @entity1261 ( @entity1261 ) priming (GCLAC) in relapsed or refractory @entity3052 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity3118 , @entity2592 , @entity1261 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity4434 ), and @entity137 of GCLAC. @entity19859 was administered at 30 mg m(-2) day(-1) * 5 and @entity2592 at 2 g m(-2) day(-1) * 5 after @entity1261 priming in 50 newly-diagnosed @entity1 ages 18-64 with @entity3052 or advanced @entity2590 ( @entity2590 ) or @entity1442 ( @entity5 ). Responses were assessed in the different cytogenetic risk groups and in @entity1 with @entity1503 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity1 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity1 with an @entity1503 ( @entity1503 ), the CR rate was 65%, compared to 85% for those without an @entity1503 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity3052 and advanced @entity9713 .

title: @entity1261 priming, @entity19859 , and high dose XXXX (GCLAC) for upfront treatment of @entity3052 , advanced @entity2590 or @entity1442 .

answer: @entity2592 :: (MESH:D003561,Chemical) :: ['cytarabine']


abstract: Prior study of the combination of @entity19859 and high dose @entity2592 with @entity1261 ( @entity1261 ) priming (GCLAC) in relapsed or refractory @entity3052 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity3118 , @entity2592 , @entity1261 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity4434 ), and @entity137 of GCLAC. @entity19859 was administered at 30 mg m(-2) day(-1) * 5 and @entity2592 at 2 g m(-2) day(-1) * 5 after @entity1261 priming in 50 newly-diagnosed @entity1 ages 18-64 with @entity3052 or advanced @entity2590 ( @entity2590 ) or @entity1442 ( @entity5 ). Responses were assessed in the different cytogenetic risk groups and in @entity1 with @entity1503 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity1 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity1 with an @entity1503 ( @entity1503 ), the CR rate was 65%, compared to 85% for those without an @entity1503 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity3052 and advanced @entity9713 .

title: @entity1261 priming, @entity19859 , and high dose @entity2592 (GCLAC) for upfront treatment of XXXX , advanced @entity2590 or @entity1442 .

answer: @entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']


abstract: Prior study of the combination of @entity19859 and high dose @entity2592 with @entity1261 ( @entity1261 ) priming (GCLAC) in relapsed or refractory @entity3052 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity3118 , @entity2592 , @entity1261 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity4434 ), and @entity137 of GCLAC. @entity19859 was administered at 30 mg m(-2) day(-1) * 5 and @entity2592 at 2 g m(-2) day(-1) * 5 after @entity1261 priming in 50 newly-diagnosed @entity1 ages 18-64 with @entity3052 or advanced @entity2590 ( @entity2590 ) or @entity1442 ( @entity5 ). Responses were assessed in the different cytogenetic risk groups and in @entity1 with @entity1503 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity1 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity1 with an @entity1503 ( @entity1503 ), the CR rate was 65%, compared to 85% for those without an @entity1503 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity3052 and advanced @entity9713 .

title: XXXX priming, @entity19859 , and high dose @entity2592 (GCLAC) for upfront treatment of @entity3052 , advanced @entity2590 or @entity1442 .

answer: @entity1261 :: (1440,Gene) :: ['G-CSF']


abstract: Prior study of the combination of @entity19859 and high dose @entity2592 with @entity1261 ( @entity1261 ) priming (GCLAC) in relapsed or refractory @entity3052 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity3118 , @entity2592 , @entity1261 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity4434 ), and @entity137 of GCLAC. @entity19859 was administered at 30 mg m(-2) day(-1) * 5 and @entity2592 at 2 g m(-2) day(-1) * 5 after @entity1261 priming in 50 newly-diagnosed @entity1 ages 18-64 with @entity3052 or advanced @entity2590 ( @entity2590 ) or @entity1442 ( @entity5 ). Responses were assessed in the different cytogenetic risk groups and in @entity1 with @entity1503 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity1 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity1 with an @entity1503 ( @entity1503 ), the CR rate was 65%, compared to 85% for those without an @entity1503 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity3052 and advanced @entity9713 .

title: @entity1261 priming, @entity19859 , and high dose @entity2592 (GCLAC) for upfront treatment of @entity3052 , advanced @entity2590 or XXXX .

answer: @entity1442 :: (MESH:D020178,Disease) :: ['advanced myeloproliferative neoplasm']


abstract: Prior study of the combination of @entity19859 and high dose @entity2592 with @entity1261 ( @entity1261 ) priming (GCLAC) in relapsed or refractory @entity3052 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity3118 , @entity2592 , @entity1261 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity4434 ), and @entity137 of GCLAC. @entity19859 was administered at 30 mg m(-2) day(-1) * 5 and @entity2592 at 2 g m(-2) day(-1) * 5 after @entity1261 priming in 50 newly-diagnosed @entity1 ages 18-64 with @entity3052 or advanced @entity2590 ( @entity2590 ) or @entity1442 ( @entity5 ). Responses were assessed in the different cytogenetic risk groups and in @entity1 with @entity1503 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity1 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity1 with an @entity1503 ( @entity1503 ), the CR rate was 65%, compared to 85% for those without an @entity1503 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity3052 and advanced @entity9713 .

title: @entity1261 priming, @entity19859 , and high dose @entity2592 (GCLAC) for upfront treatment of @entity3052 , advanced XXXX or @entity1442 .

answer: @entity2590 :: (MESH:D009190,Disease) :: ['myelodysplastic syndrome']


abstract: BACKGROUND: MicroRNA-126( @entity10013 ) has been shown to be frequently down-regulated in a variety of @entity5 and act as a potential @entity5 suppressor. However, its correlations with the clinicopathological characters of @entity5 remain unclear. METHODS: TaqMan quantitative RT-PCR was used to determine the expression level of @entity10013 in tissue samples. The associations of @entity10013 expression with clinicopathologic variables were analyzed. Kaplan-Meier survival analysis was performed to analyze the association of @entity10013 expression with @entity1349 ( @entity1349 ) of @entity1 . Univariate and multivariate Cox regression analyses were performed. RESULTS: @entity10013 expression level in @entity1 @entity5 tissues was significantly lower than that in adjacent nontumorous tissues (mean        SD: 0.59        0.44 vs. 1.00        0.51, P   <   0.0001). Decreased @entity10013 expression in @entity5 was found to be significantly associated with lymphatic invasion (P   =   0.002), distant @entity3 (P   <   0.001), FIGO stage (P   =   0.009), and histological grade (P   =   0.005). Kaplan-Meier analysis showed that @entity1 with lower levels of @entity10013 had significantly poorer survival than those with higher expression of this miRNA in @entity1 , with a 5-year @entity1349 of 45.7% and 70.9%, respectively (P   =   0.002). Multivariate analysis revealed that @entity10013 expression (HR   =   3.97, 95% CI: 2.01-20.22; P   =   0.003) was independently associated with the @entity1349 . CONCLUSION: Our data suggests the potential of @entity10013 as a prognostic biomarker for @entity5 . VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_220.

title: Decreased expression of microRNA-126 is associated with poor prognosis in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cervical cancer', 'malignancies']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']


abstract: BACKGROUND: MicroRNA-126( @entity10013 ) has been shown to be frequently down-regulated in a variety of @entity5 and act as a potential @entity5 suppressor. However, its correlations with the clinicopathological characters of @entity5 remain unclear. METHODS: TaqMan quantitative RT-PCR was used to determine the expression level of @entity10013 in tissue samples. The associations of @entity10013 expression with clinicopathologic variables were analyzed. Kaplan-Meier survival analysis was performed to analyze the association of @entity10013 expression with @entity1349 ( @entity1349 ) of @entity1 . Univariate and multivariate Cox regression analyses were performed. RESULTS: @entity10013 expression level in @entity1 @entity5 tissues was significantly lower than that in adjacent nontumorous tissues (mean        SD: 0.59        0.44 vs. 1.00        0.51, P   <   0.0001). Decreased @entity10013 expression in @entity5 was found to be significantly associated with lymphatic invasion (P   =   0.002), distant @entity3 (P   <   0.001), FIGO stage (P   =   0.009), and histological grade (P   =   0.005). Kaplan-Meier analysis showed that @entity1 with lower levels of @entity10013 had significantly poorer survival than those with higher expression of this miRNA in @entity1 , with a 5-year @entity1349 of 45.7% and 70.9%, respectively (P   =   0.002). Multivariate analysis revealed that @entity10013 expression (HR   =   3.97, 95% CI: 2.01-20.22; P   =   0.003) was independently associated with the @entity1349 . CONCLUSION: Our data suggests the potential of @entity10013 as a prognostic biomarker for @entity5 . VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_220.

title: Decreased expression of microRNA-126 is associated with poor prognosis in XXXX with @entity5 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: INTRODUCTION: Our study aimed at defining the role of @entity9940 as adjunctive therapy after extracorporeal shock wave lithotripsy (ESWL) in @entity1 with stones in the kidney and ureter. MATERIALS AND METHODS: A placebo-controlled, randomized, double-blind clinical trial prospectively performed between February 2008 and September 2009 on 150 @entity1 with 4-20 mm in diameter renal and ureteral stones referred to our ESWL center. After ESWL, all @entity1 randomly assigned to two groups (placebo and @entity9940 ). The drugs administration was started immediately after ESWL and was continued for a maximum of 30 days. RESULTS: From 150 @entity1 , 71 in control group and 70 in case group completed the study. Of 71 @entity1 (60.56%) in control group, 43 @entity1 became stone free; and other @entity1 (39.44%) did not succeed in stone expulsion during 12 weeks after ESWL. In case group of 70 @entity1 (71.4%), 50 @entity1 became stone free. Time of stone passage in most of the @entity1 happened between 20th and 30th day in control group (32.6%) and between 10th and 20th day (50%) in case group after ESWL. There is no statistically significant difference between stone passage in two groups (p = 0.116) and location of stone (p = 0.114), but there is statistically significant difference in time of stone passage from onset of treatment in case and control groups (p = 0.002). CONCLUSION: At last, this study suggested that @entity9940 facilitate earlier clearance of fragments after ESWL.

title: Is there a role for XXXX after shock wave lithotripsy in the treatment of renal and ureteral calculi?

entities_list: @entity9940 :: ('MESH:C088482', 'Chemical') :: ['tamsulosin']

answer: @entity9940 :: (MESH:C088482,Chemical) :: ['tamsulosin']